MDK-5220|cas 1796565-52-0|DC Chemicals

Cas No.:	1796565-52-0
Chemical Name:	Orexin 2 Receptor Agonist
Synonyms:	Orexin 2 Receptor Agonist;4'-methoxy-N,N-dimethyl-3'-(N-(3-((2-(3-methylbenzamido)ethyl)amino)phenyl)sulfamoyl)-[1,1'-biphenyl]-3-carboxamide;N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide;Nag26;Nag 26;GTPL9305;BCP17168;BDBM50121214;SB19183;compound 26 [PMID: 26267383];AK547566;3-
SMILES:	S(C1=C(C([H])=C([H])C(C2C([H])=C([H])C([H])=C(C(N(C([H])([H])[H])C([H])([H])[H])=O)C=2[H])=C1[H])OC([H])([H])[H])(N([H])C1=C([H])C([H])=C([H])C(=C1[H])N([H])C([H])([H])C([H])([H])N([H])C(C1=C([H])C([H])=C([H])C(C([H])([H])[H])=C1[H])=O)(=O)=O
Formula:	C₃₂H₃₄N₄O₅S
M.Wt:	586.7012
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Orexin 2 Receptor Agonist is a potent (EC50 on OX2R is 23 nM) and OX2R-selective (OX1R/OX2R EC50 ratio is 70) agonist.IC50 value: 23 nM (EC50)Target: Orexin 2 ReceptorOrexin 2 Receptor Agonist shows not only potentactivity but also high selectivity for OX2R over OX1R. In CHO cells overexpressing hOX1R and HEK-293 cells overexpressing hOX2R, compound 26 displaced [125I]orexin-A in a concentration dependent manner: 26 bound to hOX2R and hOX1R with Ki of 0.14 and 0.77 μM, respectively.[1]

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC70823	TAK-925	TAK-925 (Danavorexton) is a potent, selective, and brain-penetrant Orexin 2 receptor (OX2R) agonist with EC50 of 5.5 nM, no significant inhibition on OX1R (IC50>100 uM).TAK-925 also showed good selectivity against 106 off-target enzymes and receptors.
DC11461	TCS-OX2-29	TCS-OX2-29 is a potent and selective OX2 receptor antagonist with IC50 of 40 nM. Displays >250-fold selectivity for OX2 over OX1.
DC7513	TCS 1102	TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively).
DC5017	Suvorexant	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.Suvorexant is an analytical reference standard categorized as a diazepane sedative.Formulations containing suvorexant show abuse potential similar to zolpidem in recreational polydrug users with a history of sedative and psychedelic drug use.2 Suvorexant is regulated as a Schedule IV compound in the United States. This product is intended for use in analytical forensic applications.
DC9966	MK-1064	MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.
DC9297	MDK-5220(Orexin-2 receptor agonist)	MDK-5220(Orexin-2 receptor agonist) is the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%)
DC8173	Lemborexant(E2006)	Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.
DC7692	Almorexant HCl (Act-078573)	Almorexant(ACT078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.

MDK-5220(Orexin-2 receptor agonist)